Bolt Biotherapeutics (BOLT) Competitors $6.37 -0.16 (-2.45%) As of 02:24 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. RGLS, ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, VNDA, LXRX, and CDXSShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Its Competitors Regulus Therapeutics Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem XOMA Vanda Pharmaceuticals Lexicon Pharmaceuticals Codexis Bolt Biotherapeutics (NASDAQ:BOLT) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has more volatility & risk, BOLT or RGLS? Bolt Biotherapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Does the MarketBeat Community favor BOLT or RGLS? Regulus Therapeutics received 413 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 63.33% of users gave Regulus Therapeutics an outperform vote while only 63.28% of users gave Bolt Biotherapeutics an outperform vote. CompanyUnderperformOutperformBolt BiotherapeuticsOutperform Votes8163.28% Underperform Votes4736.72% Regulus TherapeuticsOutperform Votes49463.33% Underperform Votes28636.67% Which has better earnings & valuation, BOLT or RGLS? Regulus Therapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$3.64M3.36-$69.20M-$33.40-0.19Regulus TherapeuticsN/AN/A-$30.04M-$0.73-11.08 Does the media prefer BOLT or RGLS? In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Regulus Therapeutics. MarketBeat recorded 6 mentions for Bolt Biotherapeutics and 5 mentions for Regulus Therapeutics. Bolt Biotherapeutics' average media sentiment score of 1.29 beat Regulus Therapeutics' score of 1.29 indicating that Bolt Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regulus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate BOLT or RGLS? Bolt Biotherapeutics currently has a consensus price target of $50.00, suggesting a potential upside of 684.93%. Regulus Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 5.07%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bolt Biotherapeutics is more favorable than Regulus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Regulus Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29 Do institutionals and insiders hold more shares of BOLT or RGLS? 86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 6.1% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is BOLT or RGLS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -665.56%. Regulus Therapeutics' return on equity of -53.07% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics-665.56% -69.46% -48.55% Regulus Therapeutics N/A -53.07%-48.58% SummaryBolt Biotherapeutics beats Regulus Therapeutics on 9 of the 17 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.21M$6.93B$5.60B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-3.738.8727.2520.01Price / Sales3.36263.25412.71157.94Price / CashN/A65.8538.2534.64Price / Book2.146.617.124.70Net Income-$69.20M$144.20M$3.24B$248.05M7 Day Performance6.88%3.88%2.75%2.62%1 Month Performance-13.92%11.26%9.00%6.32%1 Year Performance-58.54%3.96%31.41%13.78% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics3.2277 of 5 stars$6.37-2.5%$50.00+684.9%-57.0%$12.21M$3.64M-3.7390News CoveragePositive NewsShort Interest ↓RGLSRegulus Therapeutics1.7549 of 5 stars$8.30+1.0%$8.50+2.4%+237.5%$574.64MN/A-7.7630Positive NewsZBIOZenas Biopharma1.3256 of 5 stars$11.92+7.2%$36.67+207.6%N/A$498.66M$15M-3.36N/ATrending NewsMYGNMyriad Genetics4.2007 of 5 stars$5.19+2.0%$14.38+177.2%-76.9%$478.40M$831.30M-3.992,600Positive NewsRIGLRigel Pharmaceuticals3.2848 of 5 stars$21.85+1.7%$36.40+66.6%+107.7%$390.50M$203.08M156.08160Positive NewsAnalyst RevisionEBSEmergent BioSolutions4.366 of 5 stars$6.50-2.0%$14.33+120.7%+3.0%$352.54M$930.30M-1.582,420VSTMVerastem3.2163 of 5 stars$6.11-4.8%$13.63+123.0%+72.0%$335.74M$10M-1.9250Positive NewsXOMAXOMA4.2381 of 5 stars$25.28+0.1%$69.50+174.9%+4.5%$302.53M$13.05M-7.2610Positive NewsVNDAVanda Pharmaceuticals4.6957 of 5 stars$4.59-0.4%$16.50+259.5%-23.5%$270.51M$201.35M-14.34290Positive NewsAnalyst RevisionLXRXLexicon Pharmaceuticals2.6889 of 5 stars$0.75-2.8%$3.67+392.1%-63.6%$269.35M$31.21M-0.99140Positive NewsCDXSCodexis3.9639 of 5 stars$2.38+0.4%$11.00+362.2%-28.9%$197.17M$49.82M-2.74250Positive NewsAnalyst Revision Related Companies and Tools Related Companies Regulus Therapeutics Alternatives Zenas Biopharma Alternatives Myriad Genetics Alternatives Rigel Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Verastem Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Lexicon Pharmaceuticals Alternatives Codexis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
